Trial
NCT03190213
Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Utah
Collaborators
Merck Sharp & Dohme LLC
Condition
Neuroendocrine Tumors
Intervention
Pembrolizumab Injection
Why stopped
Update on clinical development: after discussions with the drug manufacturer, the PI has decided to discontinue the trial.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-22